Valchlor
PreclinicalSmall molecule
Valchlor is one of 50 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
82 competitors in Cutaneous T-Cell Lymphoma
#DrugCompanyPhaseTrials
1Adcetris
PfizerPhase 3
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Poteligeo
KKyowa Kirin, Inc.
Phase 3
Istodax
TevaPhase 2
Keytruda
Merck & Co.Phase 2
Arranon
NovartisPhase 2
Afinitor
NovartisPhase 2
Fludara
SanofiPhase 2
Libtayo
RegeneronPhase 2
Humax-CD4
GenmabPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Valchlor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHelsinn Therapeutics (U.S.), Inc